XTX Topco Ltd Purchases 68,245 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

XTX Topco Ltd boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 177.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 106,773 shares of the biopharmaceutical company's stock after buying an additional 68,245 shares during the quarter. XTX Topco Ltd's holdings in Amicus Therapeutics were worth $871,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of FOLD. Virtus Fund Advisers LLC acquired a new stake in Amicus Therapeutics during the 4th quarter worth about $29,000. Covestor Ltd increased its position in shares of Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 2,312 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amicus Therapeutics during the fourth quarter valued at approximately $59,000. GAMMA Investing LLC lifted its position in shares of Amicus Therapeutics by 1,610.8% in the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 7,007 shares in the last quarter. Finally, Bryce Point Capital LLC purchased a new stake in shares of Amicus Therapeutics in the first quarter valued at $100,000.

Analyst Upgrades and Downgrades

FOLD has been the subject of a number of research analyst reports. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Wall Street Zen upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday. UBS Group lifted their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, The Goldman Sachs Group reduced their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, Amicus Therapeutics has an average rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock traded up $0.16 on Tuesday, reaching $6.99. 4,595,726 shares of the stock were exchanged, compared to its average volume of 4,337,626. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $12.65. The firm has a fifty day moving average price of $6.06 and a two-hundred day moving average price of $7.40. The stock has a market cap of $2.15 billion, a PE ratio of -58.25 and a beta of 0.53.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.